

reproductive toxicity was > 12,000 ppm. Offspring effects were not observed at dose levels that did not produce parental toxicity. There is no evidence that developing offspring are more sensitive than adults to the effects of trifloxysulfuron-sodium.

FFDCA section 408 provides that EPA may apply an additional safety factor for infants and children in the case of threshold effects to account for prenatal and postnatal toxicity and the completeness of the data base. Based on the current toxicological requirements, the data base for trifloxysulfuron-sodium relative to prenatal and postnatal effects for children is complete. Further, for trifloxysulfuron-sodium, the developmental studies showed no increased sensitivity in fetuses as compared to maternal animals following *in-utero* exposures in rats and rabbits, and no increased sensitivity in pups as compared to the adults in the multi-generation reproductive toxicity study. Therefore, it is concluded that an additional uncertainty factor is not warranted to protect the health of infants and children and that a RfD of 0.15 mg/kg/day is appropriate for assessing aggregate risk to infants and children of trifloxysulfuron-sodium.

Assuming tolerance level residues and 100% of crops treated, less than 0.1% of the trifloxysulfuron-sodium chronic RfD is utilized in the population subgroup all infants (>1 year old). Therefore, based on the completeness and reliability of the toxicity data base, Syngenta concludes that there is reasonable certainty that no harm will result to infants and children from aggregate exposure to trifloxysulfuron-sodium residues.

#### *F. International Tolerances*

There are no Codex MRLs established for residues of trifloxysulfuron-sodium on cottonseed, cotton byproducts, citrus, almonds, sugarcane or tomatoes.

[FR Doc. 03-6822 Filed 3-20-03; 8:45 am]

BILLING CODE 6560-50-S

## ENVIRONMENTAL PROTECTION AGENCY

[FRL-7471-2]

### Strategic Plan for North American Cooperation in the Conservation of Biodiversity—Draft for Public Review

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice of availability.

**SUMMARY:** Comments are requested on the final draft of the *Strategic Plan for*

*North American Cooperation in the Conservation of Biodiversity* (Strategic Plan). The Strategic Plan has been prepared by the Secretariat of the Commission for Environmental Cooperation (CEC), under the North American Agreement on Environmental Cooperation, in coordination with representatives from Canada, Mexico, and the United States. The Strategic Plan will be used to guide the CEC Council, its Biodiversity Conservation Working Group, and the CEC Secretariat in their work with stakeholders in cooperatively defining and implementing mutually beneficial biodiversity conservation activities in North America. Comments will be categorized and responses will be developed for each category. Responses to comment categories will be published in the **Federal Register** within 45 days of the closing date for comments. Changes to the final draft of the Strategic Plan, to be made in response to comments, will be discussed with representatives from Canada, Mexico and the CEC Secretariat.

**DATES:** Written comments will be accepted for 30 calendar days. Please submit or postmark written comments on the final draft document by April 21, 2003.

**ADDRESSES:** Comments should be sent to Patrick Cotter, Office of International Affairs (2260R), U.S. Environmental Protection Agency, and 1300 Pennsylvania Avenue, NW., Washington, DC 20004. Faxed comments should be sent to Patrick Cotter at (202) 565-2409. Comments can also be sent by email to [Cotter.Patrick@epa.gov](mailto:Cotter.Patrick@epa.gov).

**Access to the Document:** The complete text of the final draft document, in English, is available through a link on the EPA Office of International Affairs' Web site at: <http://www.epa.gov/international/trade/index.html>, or you may access the document directly on the CEC's Web site at: [http://www.cec.org/pubs\\_docs/documents/index.cfm?varlan=english&ID=1088](http://www.cec.org/pubs_docs/documents/index.cfm?varlan=english&ID=1088). Copies of the final draft document can be obtained in electronic or hard copy format by request from Patrick Cotter at the above mailing address, email address or by calling (202) 564-6414.

**FOR FURTHER INFORMATION CONTACT:** Patrick Cotter by telephone at (202) 564-6414 or by email at [Cotter.Patrick@epa.gov](mailto:Cotter.Patrick@epa.gov).

Dated: March 17, 2003.

**Dona M. Harris,**

*Acting Director, Office of Management Operations, Office of International Affairs.*  
[FR Doc. 03-6818 Filed 3-20-03; 8:45 am]

BILLING CODE 6560-50-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 02N-0281]

#### Agency Information Collection Activities; Announcement of OMB Approval; General Administrative Procedures: Citizen Petitions; Petition for Reconsideration or Stay of Action; Advisory Opinions

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "General Administrative Procedures: Citizen Petitions; Petition for Reconsideration or Stay of Action; Advisory Opinions" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** JonnaLynn P. Capezzuto, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of December 18, 2002 (67 FR 77498), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0183. The approval expires on March 31, 2006. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: March 14, 2003.

**William K. Hubbard,**

*Associate Commissioner for Policy and Planning.*

[FR Doc. 03-6739 Filed 3-20-03; 8:45 am]

BILLING CODE 4160-01-S